Corporate Profile
Zura Bio is a clinical-stage, multi-asset immunology company dedicated to developing novel therapies for a range of autoimmune and inflammatory diseases with unmet needs. The Company’s pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura Bio’s lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies in adults, including TibuSHIELD for hidradenitis suppurativa and TibuSURE for systemic sclerosis. A third study, NEXUS-PMR, for polymyalgia rheumatica is planned to be initiated by year-end 2026. Additional product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.
Minimum 15 minutes delayed. Source: LSEG